Arno Therapeutics, Inc.

Creating the next generation of cancer treatments

May 15, 2013
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting more »
May 10, 2013
Arno Therapeutics to Collaborate with Clarient for Development of Diagnostic Test more »
April 8, 2013
Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
Data Presented Today at AACR Annual Meeting 2013 more »
March 19, 2013
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel more »
January 31, 2013
Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors more »

December 19, 2012
Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds more »
December 5, 2012
Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone more »
November 27, 2012
Arno Therapeutics Completes $12.7 Million Financing more »
November 9, 2012
Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone more »
June 7, 2012
Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe more »
May 11, 2012
Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe more »
February 21, 2012
Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors more »
February 14, 2012
Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug more »

June 27, 2011
Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer more »
June 23, 2011
Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue more »
April 28, 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer more »

September 13, 2010
Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds more »
June 17, 2010
Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC) more »

April 19, 2013
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel more »
March 19, 2013
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel more »
December 17, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM) more »
December 15, 2009
Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42 more »
August 27, 2009
Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway more »
July 23, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome more »
May 27, 2009
Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting more »
May 11, 2009
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway more »
May 4, 2009
Arno Therapeutics to Deregister its Common Stock under the Exchange Act more »
March 31, 2009
Arno Therapeutics Reports 2008 Year-End Financial Results more »
March 17, 2009
FDA Accepts IND for Arno Therapeutics’ Pan-DAC/Akt Inhibitor, AR-42 more »

November 14, 2008
Arno Therapeutics Announces Third Quarter 2008 Financial Results more »
November 3, 2008
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference more »
October 30, 2008
Arno Therapeutics Appoints William F. Hamilton to Board of Directors more »
September 3, 2008
Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director more »
August 18, 2008
Arno Therapeutics Announces Second Quarter 2008 Financial Results more »
August 14, 2008
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer more »
July 16, 2008
Arno Therapeutics Announces New Ticker Symbol more »
June 5, 2008
BioWorld Today - Arno Gets $18M Plus Market Access in Reverse Merger more »
June 4, 2008
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger more »
Jan. 28, 2008
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds more »

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax
info@arnothera.com